Login to Your Account



With Flurizan In Phase III, Myriad Bringing In $130M

By Karen Pihl-Carey


Monday, November 7, 2005
As lead product Flurizan is being tested in a Phase III trial for Alzheimer's disease, Myriad Genetics Inc. priced a public offering of its common stock to raise $129.5 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription